Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application

Area of Science:

• Hematology
• Immunology
• Transplantation

Background:

• Significant advancements in human leukocyte antigen (HLA) typing and graft versus host disease (GvHD) prevention have reduced GvHD incidence in related and unrelated transplants.
• Post-transplant cyclophosphamide (PTCY) has revolutionized haploidentical transplantation by mitigating bidirectional alloreactivity.

Purpose of the Study:

• To review the current data on the efficacy and safety of using PTCY in HLA-matched stem cell transplantation.
• To evaluate the potential of PTCY as a GvHD prophylaxis strategy in HLA-matched settings.

Main Methods:

• Systematic review of published literature and clinical trial data.
• Analysis of studies investigating PTCY use in HLA-matched sibling and unrelated donor transplants.
• Examination of GvHD incidence, overall survival, and other relevant outcomes.

Main Results:

• PTCY has demonstrated promising results in reducing GvHD in haploidentical transplants.
• Emerging data suggests PTCY may be effective in HLA-matched settings, though further research is needed.
• Comparison of outcomes between PTCY and traditional GvHD prophylaxis in HLA-matched transplants.

Conclusions:

• PTCY is a viable and effective strategy for GvHD prevention in haploidentical transplants.
• The application of PTCY in HLA-matched transplantation warrants further investigation and clinical trials.
• Optimizing PTCY protocols may enhance its utility across different donor types in stem cell transplantation.